Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron COVID-19 Cocktail’s Flame To Burn Brightly But Unclear For How Long

Antibody Products Will Be An Important Option Until Vaccines Reduce Infections

Executive Summary

Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.

You may also be interested in...



EMA Reviewing Two MAb Combinations For COVID-19

The European Medicines Agency's special review process that was used to help EU member states issue emergency use approvals for dexamethasone in COVID-19 patients is now being applied to two antibody combinations from Regeneron/Roche and Lilly.

Regeneron Antibodies Prevent Symptomatic COVID-19 In Interim Phase III Data

The company said data show a lower overall infection rate and no symptomatic infections among participants receiving the drug, compared with placebo.

Lilly’s Neutralizing Antibodies Reduce Risk Of Serious COVID-19 Outcomes By 70%

The bamlanivimab/etesevimab combo, filed for US emergency authorization in November, shows ability to reduce risk of hospitalization or death in COVID-19 patients. Lilly also sees prevention role for bamlanivimab.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143365

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel